Docs concerned for the use of Favipiravir for COVID in India
By MYBRANDBOOK
Favipiravir, an antiviral drug for the treatment of mild-to-moderate COVID-19 cases, was launched recently by Glenmark Pharmaceuticals. According to reports, the drug has been launched after it received approval from the Drug Controller General of India to manufacture and market the medicine.
The antiviral drug Favipiravir has been approved in Japan since 2014 for the treatment of novel or re-emerging influenza virus infections. It works by inhibiting viral replication and reducing the viral load in a patient. It is an experimental medicine being repurposed for COVID-19.
According to Glenn Saldanha, Chairman and Managing Director of Glenmark Pharmaceuticals the approval has come at a time when cases in India are spiralling, putting tremendous pressure on our healthcare system.
The drug FabiFlu will be available as a prescription-based medication for Rs 103 per tablet, with the recommended dose being 1800 mg twice daily on day 1, followed by 800 mg twice daily up to day 14.
The drug is not recommended in patients with severe renal, hepatic impairment, and in pregnant and lactating women.
Glenmark has claimed that Favipiravir shows clinical improvements of up to 88% in COVID-19 disease, with a rapid reduction in viral load by 4 days.
Favipiravir is being studied in at least 18 trials around the world as a potential treatment for COVID-19. Earlier last month, Glenmark also announced that it is conducting another clinical trial to evaluate the efficacy of two antivirals Favipiravir and Umifenovir as a combination therapy in moderate hospitalized adult COVID-19 patients in India.
But according to doctors there is insufficient evidence in favour of the medicine. A large portion of doctors don’t feel there is any real requirement of the medicine for mild attacks. They feel there is so much panic and fear around the disease that they will be forced to arrange for the medicine even if they have no funds - when in reality, a mild COVID case may recover either without medication, or with medicines costing no more than Rs 10.
Singapore to remove One-Time Passwords from Bank Accounts
According to the Monetary Authority of Singapore, clients who utilise secur...
Is 375 million Airtel subscribers database breached?
When a hacker claims to have accessed and put up for sale a customer databa...
The government of India intends to construct a single portal f
A single portal will be launched by the Indian government to list all of it...
OpenAI offers GPT-4o, a faster model available to all users at
GPT-4o, a faster and more sophisticated AI model, is made available to all...
Icons Of India : Kumar Mangalam Birla
Aditya Birla Group chairman Kumar Mangalam Birla recently made a comeb...
Icons Of India : AMIT CHADHA
Amit Chadha serves as the CEO and Managing Director of L&T Technology ...
Icons Of India : Deepak Sharma
Deepak Sharma spearheads Schneider Electric India. He brings with him ...
TCIL - Telecommunications Consultants India Limited
TCIL is a government-owned engineering and consultancy company...
C-DOT - Center of Development of Telematics
India’s premier research and development center focused on telecommu...
IREDA - Indian Renewable Energy Development Agency Limited
IREDA is a specialized financial institution in India that facilitates...
Indian Tech Talent Excelling The Tech World - Shantanu Narayen, CEO- Adobe Systems Incorporated
Shantanu Narayen, CEO of Adobe Systems Incorporated, is renowned for h...
Indian Tech Talent Excelling The Tech World - PADMASREE WARRIOR, Founder, President & CEO - Fable
Padmasree Warrior, the Founder, President, and CEO of Fable, is revolu...
Indian Tech Talent Excelling The Tech World - JAY CHAUDHRY, CEO – Zscaler
Jay Chaudhry, an Indian-American technology entrepreneur, is the CEO a...